PART I Item 1. Bu siness. Overview We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption. Our objective is to develop product candidates that address disease through targeted mechanisms, such as removing pathogenic proteins, repla...
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001193125-26-071593 | EDGAR | 87K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027758 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021183 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005111 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001979 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008860 | EDGAR | — |
| 2020-03-24 | 2019-12-31 | 0001564590-20-012520 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001564590-19-009358 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269592 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105050 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066987 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122328 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092814 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055682 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060270 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038023 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017874 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023249 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014810 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007846 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-25 | 0001193125-26-071557 | EDGAR | 2K words |
| 2025-12-12 | 0001193125-25-317554 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269537 | EDGAR | — |
| 2025-10-21 | 0001193125-25-245102 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105023 | EDGAR | — |
| 2025-06-13 | 0001193125-25-140731 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066945 | EDGAR | — |
| 2025-03-28 | 0000950170-25-046756 | EDGAR | — |
| 2025-03-10 | 0001193125-25-050448 | EDGAR | — |
| 2025-02-26 | 0000950170-25-027734 | EDGAR | — |
123 total filings indexed. 93 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001653087 |
| Ticker | ALEC |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.alector.com |
| Listed | 2019-02-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report